CurrentCardio
Get Weekly

Topic · page 3 of 6

Cardiometabolic & kidney

Diabetes, obesity, CKD and their cardiovascular or cardiorenal outcomes, SGLT2i/GLP-1 RA outside a primary HF population

Briefs 81–120 of 238 placed here, newest publication first

Briefs in Cardiometabolic & kidney

Newest publication first

  1. JACC Adv

    Associations of Socioeconomic Status With Cardiorenal Metabolic Multimorbidity: Evidence From the UK Biobank Cohort

    Cohort study

  2. Am Heart J

    Empagliflozin and functional aerobic capacity in individuals with increased risk of heart failure: The Empire Prevent Cardiac trial

    Randomised controlled trial

  3. JAMA Cardiol

    Cardiovascular-Kidney-Metabolic Medication Eligibility Across National Survey, Community-Based, and Ambulatory Healthcare Samples

    Cross-sectional study

  4. JAMA Cardiol

    Cost-Effectiveness of Semaglutide for Secondary Prevention of Cardiovascular Disease in US Adults

    Cohort study

  5. Eur Heart J Cardiovasc Imaging

    Abnormal myocardial perfusion reserve and myocardial infarction determine cardiovascular outcomes in type 2 diabetes mellitus

    Cohort study

  6. JACC Adv

    Hypertension Subtypes and Diabetes: Joint Associations in the National Health and Nutrition Examination Survey

    Cross-sectional study

  7. Eur J Prev Cardiol

    Combination of cardioprotective glucose-lowering drugs and statins on cardiovascular mortality in diabetes: a nationwide cohort study

    Cohort study

  8. Heart

    Cardiovascular benefits of obesity therapies: an overview of obesity medicines and metabolic bariatric surgery

    Research article

  9. Circulation

    Prospective Associations of Obesity and Obesity Severity With 9 Cardiovascular Outcomes: The Cross-Cohort Collaboration

    Cohort study

  10. Circ Cardiovasc Interv

    Reno-Protective Effects of SGLT2 Inhibitors in Patients With Diabetes Undergoing Percutaneous Coronary Intervention: Insights From the BMC2 Registry

    Cohort study

  11. J Am Coll Cardiol

    MASLD, MASH, and the CKM Spectrum: A Roadmap for Multiorgan Clinical Trial Design

    Research article

  12. Circ Cardiovasc Imaging

    Prognostic Significance of Noninvasive Simultaneous Renal and Cardiac Perfusion: Interrogating Mechanisms of Cardiovascular-Kidney Interactions

    Cohort study

  13. JACC Adv

    VExUS Point-of-Care Ultrasound Tool to Detect Changes in Volume Status: A Prospective Observational Study

    Cohort study

  14. Am Heart J

    Safety of a remote disease management program to improve sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists prescribing in type 2 diabetes with elevated cardiovascular or kidney risk

    Randomised controlled trial

  15. JACC Adv

    Wireless Movement Activity and Cardiometabolic Disease Risk in Historical Redlined Areas

    Research article

  16. JACC Adv

    Health Plan-Based Atherosclerosis Imaging for Members with Diabetics: Utilization and Impact on Subsequent Episodes of Care

    Cohort study

  17. J Am Coll Cardiol

    Blood Pressure Levels and Outcomes in Type 2 Diabetes: Dose-Response Meta-Analysis of 5.87 Million Cohort Participants

    Meta-analysis

  18. ESC Heart Fail

    Clinical risk prediction models for worsening heart failure events and all-cause mortality in adults with mild-to-moderate chronic kidney disease

    Diagnostic or prognostic study

  19. Eur Heart J Cardiovasc Pharmacother

    Cardiovascular safety of 5α-reductase inhibitors in people with benign prostatic hyperplasia and type 2 diabetes: a propensity score-matched analysis

    Cohort study

  20. Circulation

    Socioeconomic and Structural Barriers to Addressing Obesity in Communities: A Scientific Statement From the American Heart Association

    Guideline or statement

  21. Eur J Prev Cardiol

    Mortality and cumulative cardiovascular risk factor control in patients with type 2 diabetes: a nationwide population-based cohort study

    Cohort study

  22. JAMA Cardiol

    Chronic Kidney Disease Prevalence and Awareness Among US Adults

    Cross-sectional study

  23. JAMA Cardiol

    Rationale, Design, and Baseline Clinical Characteristics of the Ziltivekimab Cardiovascular Outcomes Trial: Interleukin-6 Inhibition and Atherosclerotic Event Rate Reduction

    Randomised controlled trial

  24. Eur J Prev Cardiol

    The role of inflammation in longitudinal renal function decline and incident chronic kidney disease: the multi-ethnic study of atherosclerosis

    Cohort study

  25. N Engl J Med

    Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes

    Randomised controlled trial

  26. Eur J Prev Cardiol

    Night shift work and its interaction with sleep duration and chronotype, and risk of cardiovascular–kidney–metabolic diseases in the UK Biobank

    Cohort study

  27. Eur Heart J

    Diabetes and sudden cardiac death: a Danish nationwide study

    Cohort study

  28. Eur Heart J

    Underweight and cardiovascular risk in Type 2 diabetes: a Korean nationwide study

    Cohort study

  29. Nat Med

    Cardiovascular outcomes of semaglutide and tirzepatide for patients with type 2 diabetes in clinical practice

    Cohort study

  30. Eur J Heart Fail

    Sodium–Glucose co-Transporter 2 Inhibitors in Severe Estimated Glomerular Filtration Rate Deterioration Across Cardiovascular-Kidney-Metabolic Conditions: A Pooled Analysis of Randomized Trials

    Meta-analysis

  31. N Engl J Med

    Fish-Oil Supplementation and Cardiovascular Events in Patients Receiving Hemodialysis

    Randomised controlled trial

  32. J Am Coll Cardiol

    Risk of Hyperkalemia With Empagliflozin, Finerenone, or Both: Secondary Analysis of the CONFIDENCE Randomized Trial

    Secondary analysis

  33. Eur J Prev Cardiol

    Data-driven cluster analysis identifies distinct types of cardiovascular-kidney-metabolic syndrome

    Cohort study

  34. JAMA Cardiol

    Cumulative Cardiovascular Health Score Through Young Adulthood and Cardiovascular and Kidney Outcomes in Midlife

    Cohort study

  35. JAMA Cardiol

    Discontinuation of Semaglutide Among Older Adults With Diabetes in the US and Japan

    Cohort study

  36. Lancet

    Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial

    Secondary analysis

  37. Eur Heart J

    Urinary tract infection and continuation of sodium-glucose cotransporter-2 inhibitors in diabetic patients

    Cohort study

  38. Eur J Prev Cardiol

    Accelerometer-derived ‘weekend warrior’ physical activity and incident cardiovascular disease among people with diabetes

    Cohort study

  39. Eur J Heart Fail

    Incidence of Major Cardiovascular Events in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease in the General Population

    Cohort study

  40. Eur J Prev Cardiol

    Erythrocyte odd-chain fatty acids and the risk of cardiometabolic diseases: a prospective study and updated meta-analysis

    Meta-analysis

All 238 Briefs in ExploreShowing Briefs 81–120 of 238, newest first